Fig. 11From: Indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors in clinical trials for cancer immunotherapyThe development of navoximod (PDB code: 6O3I). The heme site is colored in green. The inhibitor navoximod is displayed in yellow stick. The H-bonding interactions between Navoximod and the IDO1 protein matrix are indicated by the blue dotted linesBack to article page